Safety Profile

UPTRAVI—Safety Profile1

ADVERSE REACTIONS OCCURRING MORE FREQUENTLY WITH UPTRAVI COMPARED WITH PLACEBO BY ≥3% IN THE GRIPHON TRIAL

These adverse reactions were more frequent during the titration phase.

  • Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo
  • Median duration of exposure to UPTRAVI was 1.4 years

Postmarketing Experience

The following adverse reactions have been identified during postapproval use of UPTRAVI.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  • Symptomatic hypotension

Help your patients be prepared for potential adverse reactions and how to manage them

  • Adverse Reactions Management Tool: Learn about adverse reactions common to prostacyclin-class therapies
  • UPTRAVI Dose Adjustment Phase Guide for patients: Use this guide for patients who are starting UPTRAVI to help set goals and expectations for treatment. After discussion, give patients the guide to help them track and share how they’re feeling